Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Subcutaneous Injection: Under the skin
(PubMed) Stevens VL, McCullough ML, Sun J, Gapstur SM
The COA records the HPLC-verified purity and identity data for that specific batch
Its once-weekly injection schedule makes it a convenient and effective option for long-term therapy
2. Osteoporosis & Bone Density
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
US$ 22.60
US$ 22.29
US$ 25.28
US$ 27.62
